Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-10T08:14:32.041Z Has data issue: false hasContentIssue false

II. the Incidence of Compliance Problems, Side-effects, Neurotic Symptoms and Depression

Published online by Cambridge University Press:  29 January 2018

Summary

Seven years after the completion of the original trial, over 73% of patients were maintained on depot neuroleptics, and 70% had received such medication for over seven years. About 40% had presented with a problem of compliance at some time, and there was a significant correlation between poor compliance and in-patient admissions and schizophrenic relapses. The prevalence of parkinsonian side-effects, akathisia, and tardive dyskinesia was low. Non-psychotic symptoms were common, even in the absence of acute psychosis. Depression was found in a subgroup of patients; it was frequently reported as an indication for admission during follow-up period, and seemed to be part of the schizophrenic illness rather than a result of antipsychotic drug treatment.

Type
Long-term Depot Maintenance of Chronic Schizophrenic Out-patients: The Seven Year Follow-up of the Medical Research Council Fluphenazine/Placebo Trial
Copyright
Copyright © 1985 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

eLetters

No eLetters have been published for this article.